Cargando…

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

BACKGROUND: In recurrent malignant gliomas (MGs), a high rate of haematological toxicity is observed with the use of fotemustine at the conventional schedule (100 mg/m(2 )weekly for 3 consecutive weeks followed by triweekly administration after a 5-week rest period). Also, the impact of O6-methylgua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fabi, Alessandra, Metro, Giulio, Russillo, Michelangelo, Vidiri, Antonello, Carapella, Carmine Maria, Maschio, Marta, Cognetti, Francesco, Jandolo, Bruno, Mirri, Maria Alessandra, Sperduti, Isabella, Telera, Stefano, Carosi, Mariantonia, Pace, Andrea
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667532/ https://www.ncbi.nlm.nih.gov/pubmed/19335893 http://dx.doi.org/10.1186/1471-2407-9-101

Ejemplares similares

Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center
por: Fabi, Alessandra, et al.
Publicado: (2011)

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
por: Vaccaro, V., et al.
Publicado: (2014)

The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma
por: Villani, Veronica, et al.
Publicado: (2015)

The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine
por: Maschio, Marta, et al.
Publicado: (2009)

Quantitative analysis of CT-perfusion parameters in the evaluation of brain gliomas and metastases
por: Di Nallo, Anna Maria, et al.
Publicado: (2009)

Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study
por: Cordone, Iole, et al.
Publicado: (2017)

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
por: Fabi, Alessandra, et al.
Publicado: (2012)

Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation
por: Vidiri, Antonello, et al.
Publicado: (2012)

Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls
por: Cordone, Iole, et al.
Publicado: (2016)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas
por: Regazzo, Giulia, et al.
Publicado: (2016)

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
por: Cuppone, Federica, et al.
Publicado: (2011)

How Dual-Energy Contrast-Enhanced Spectral Mammography Can Provide Useful Clinical Information About Prognostic Factors in Breast Cancer Patients: A Systematic Review of Literature
por: Vasselli, Federica, et al.
Publicado: (2022)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Regulation of Inflammatory and Proliferative Pathways by Fotemustine and Dexamethasone in Endometriosis
por: Genovese, Tiziana, et al.
Publicado: (2021)

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
por: Rossi, Valentina, et al.
Publicado: (2019)

Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report
por: Allegretti, Matteo, et al.
Publicado: (2023)

Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
por: Santoni, Matteo, et al.
Publicado: (2013)

Sexual dysfunction following surgery for rectal cancer - a clinical and neurophysiological study
por: Pietrangeli, Alberto, et al.
Publicado: (2009)

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
por: Fabi, Alessandra, et al.
Publicado: (2016)

Surgical treatment of cerebellar metastases in elderly patients: A threshold that moves forward?
por: Telera, Stefano, et al.
Publicado: (2023)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen
por: Musso, Maurizio, et al.
Publicado: (2015)

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
por: Lee, S. M., et al.
Publicado: (1993)

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

Fotemustine: A Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas
por: Beauchesne, Patrick
Publicado: (2012)

Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients
por: Ferraresi, Virginia, et al.
Publicado: (2010)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
por: Stagno, Anna, et al.
Publicado: (2021)

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2
por: Becker, J C, et al.
Publicado: (2002)

Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme
por: Liu, Zhiguang, et al.
Publicado: (2015)

The Glioma-IRE project − Molecular profiling in patients with glioma: steps toward an individualized diagnostic and therapeutic approach
por: Villani, Veronica, et al.
Publicado: (2023)

Breast cancer metastasis: Is it a matter of OMICS and proper ex-vivo models?
por: Cioce, Mario, et al.
Publicado: (2022)

Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)
por: Soffietti, Riccardo, et al.
Publicado: (2013)

Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation
por: Ristić-Fira, Aleksandra M, et al.
Publicado: (2009)

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
por: Infante, Marco, et al.
Publicado: (2019)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vv9au7g3qqqgc0bp15qdec2jlv